Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Gehrau, Ricardo C ^a   D'Astolfo, Diego S ^a   Dumur, Catherine I ^b   Bocco, José L ^a   Koritschoner, Nicolás P ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KRUPPEL LIKE FACTOR 6; KLF6 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; ONCOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; CELL FRACTIONATION; CELL NUCLEUS; FEMALE; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY;

MAMMALIA;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KRUPPEL-LIKE TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; SUBCELLULAR FRACTIONS;

EID: 77952539260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008929     Document Type: Article

References (52)

1. Ghaleb AM, Katz JP, Kaestner KH, Du JX, Yang VW (2007) Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene 26: 2365-2373.
2. Kaczynski J, Cook T, Urrutia R (2003) Sp1- and Kruppel-like transcription factors. Genome Biol 4: 206.
3. Rowland BD, Peeper DS (2006) KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 6: 11-23.
4. Suske G, Bruford E, Philipsen S (2005) Mammalian SP/KLF transcription factors: bring in the family. Genomics 85: 551-556.
5. Gehrau RC, D'Astolfo DS, Prieto C, Bocco JL, Koritschoner NP (2005) Genomic organization and functional analysis of the gene encoding the Kruppel-like transcription factor KLF6. Biochim Biophys Acta 1730: 137-146.
6. Koritschoner NP, Bocco JL, Panzetta-Dutari GM, Dumur CI, Flury A, et al. (1997) A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J Biol Chem 272: 9573-9580.
7. Slavin D, Sapin V, Lopez-Diaz F, Jacquemin P, Koritschoner N, et al. (1999) The Kruppel-like core promoter binding protein gene is primarily expressed in placenta during mouse development. Biol Reprod 61: 1586-1591.
8. Bureau C, Peron JM, Bouisson M, Danjoux M, Selves J, et al. (2008) Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J Gastroenterol Hepatol 23: 78-86.
9. Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, et al. (2007) Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer 121: 1390-1395.
10. Miyaki M, Yamaguchi T, Iijima T, Funata N, Mori T (2006) Difference in the role of loss of heterozygosity at 10p15 (KLF6 locus) in colorectal carcinogenesis between sporadic and familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer patients. Oncology 71: 131-135.
11. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, et al. (2003) Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 162: 1349-1354.
12. Narla G, Heath KE, Reeves HL, Li D, Giono LE, et al. (2001) KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294: 2563-2566.
13. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, et al. (2008) Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134: 1521-1531.
14. Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, et al. (2009) Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer 45: 666-676.
15. Ito G, Uchiyama M, Kondo M, Mori S, Usami N, et al. (2004) Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 64: 3838-3843.
16. Agell L, Hernandez S, de Muga S, Lorente JA, Juanpere N, et al. (2008) KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 21: 1470-1478.
17. Boyault S, Herault A, Balabaud C, Zucman-Rossi J (2005) Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology 41: 681-682; author reply 682-683.
18. Kohler B, Wolter M, Blaschke B, Reifenberger G (2004) Absence of mutations in the putative tumor suppressor gene KLF6 in glioblastomas and meningiomas. Int J Cancer 111: 644-645.
19. Koivisto PA, Zhang X, Sallinen SL, Sallinen P, Helin HJ, et al. (2004) Absence of KLF6 gene mutations in human astrocytic tumors and cell lines. Int J Cancer 111: 642-643.
20. Lievre A, Landi B, Cote JF, Veyrie N, Zucman-Rossi J, et al. (2005) Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. Oncogene 24: 7253-7256.
21. Montanini L, Bissola L, Finocchiaro G (2004) KLF6 is not the major target of chromosome 10p losses in glioblastomas. Int J Cancer 111: 640-641.
22. Matsumoto N, Kubo A, Liu H, Akita K, Laub F, et al. (2006) Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357-1365.
23. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, et al. (2007) In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26: 4428-4434.
24. Sirach E, Bureau C, Peron JM, Pradayrol L, Vinel JP, et al. (2007) KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ 14: 1202-1210.
25. D'Astolfo DS, Gehrau RC, Bocco JL, Koritschoner NP (2008) Silencing of the transcription factor KLF6 by siRNA leads to cell cycle arrest and sensitizes cells to apoptosis induced by DNA damage. Cell Death Differ 15: 613-616.
26. Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, et al. (2004) A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene 23: 8196-8205.
27. Tahara E, Kadara H, Lacroix L, Lotan D, Lotan R (2009) Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 8.
28. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, et al. (2004) Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 64: 3885-3891.
29. Sun M, Yang YR, Huang J, Li H, Lu YP, et al. (2006) [Effect of KLF6 on prostate cancer cell line PC-3 by transgenic method]. Zhonghua Nan Ke Xue 12: 502-504509.
30. Guo H, Lin Y, Zhang H, Liu J, Zhang N, et al. (2007) Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 8: 110.
31. Payne SJ, Bowen RL, Jones JL, Wells CA (2008) Predictive markers in breast cancer-the present. Histopathology 52: 82-90.
32. Faratian D, Bartlett J (2008) Predictive markers in breast cancer-the future. Histopathology 52: 91-98.
33. Tang P, Hajdu SI, Lyman GH (2007) Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol 19: 63-67.
34. Irvine T, Fentiman IS (2007) Biology and treatment of ductal carcinoma in situ. Expert Rev Anticancer Ther 7: 135-145.
35. Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602.
36. Wiechmann L, Kuerer HM (2008) The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 112: 2130-2142.
37. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, et al. (2004) Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 10: 2709-2719.
38. Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, et al. (2000) Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 60: 6488-6495.
39. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, et al. (2005) Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24: 3319-3327.
40. Chen C, Bhalala HV, Qiao H, Dong JT (2002) A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21: 6567-6572.
41. Sun R, Chen X, Yang VW (2001) Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation. J Biol Chem 276: 6897-6900.
42. Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, et al. (2006) Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res 12: 2442-2448.
43. Azim H, Azim HA Jr (2008) Targeting Her-2/neu in breast cancer: as easy as this! Oncology 74: 150-157.
44. Benson JR, Weaver DL, Mittra I, Hayashi M (2003) The TNM staging system and breast cancer. Lancet Oncol 4: 56-60.
45. Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, et al. (2008) KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 118: 2711-2721.
46. Blanchon L, Bocco JL, Gallot D, Gachon AM, Lemery D, et al. (2001) Co-localization of KLF6 and KLF4 with pregnancy-specific glycoproteins during human placenta development. Mech Dev 105: 185-189.
47. Ratziu V, Lalazar A, Wong L, Dang Q, Collins C, et al. (1998) Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci U S A 95: 9500-9505.
48. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, et al. (2002) Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100: 4001-4010.
49. Liu J, Du T, Yuan Y, He Y, Tan Z, et al. (2009) KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway. Mol Cell Biochem.
50. Grizzle WE, Myers RB, Manne U, Stockard CR, Harkin LE, et al. (1998) Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M, Walaszek Z, eds. Methods in molecular medicine: tumor marker protocols. TotowaNJ: Humana Press, Inc. pp 161-179.
51. Grizzle WE, Myers RBM, Manne U, S S (1998) Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M, Walaszek Z, eds. Methods in molecular medicine: tumor marker protocols. TotowaNJ: Humana Press, Inc. pp 143-160.
52. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43.